Who makes Drug: "Tocilizmab"?

Drug: "Tocilizmab" is developed by Shinshu University.

What development phase is Drug: "Tocilizmab" in?

Drug: "Tocilizmab" is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Drug: "Tocilizmab"

Shinshu University · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Drug: "Tocilizmab"
Sponsor	Shinshu University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy (PHASE2)
Usefulness of Non TNF Usage in RA Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Drug: "Tocilizmab" CI brief — competitive landscape report
Drug: "Tocilizmab" updates RSS · CI watch RSS
Shinshu University portfolio CI